Literature DB >> 30039636

Dyslipidaemia and statin use in individuals aged 10 to <40 years in the T1D Exchange clinic registry.

Sarah K Lyons1, Claire T Boyle2, Daniel J DeSalvo1, Michael R Rickels3, Lauren K Wood Heickman4, Kellee M Miller2, Nicole C Foster2, Mark A Clements5.   

Abstract

For individuals aged 10 to <40 years with type 1 diabetes and dyslipidaemia, US national guidelines recommend consideration of statin therapy based on age, low-density lipoprotein cholesterol (LDL-C) level and other cardiovascular risk factors. We evaluated dyslipidaemia prevalence, statin therapy use, and associations between not meeting target LDL-C [<100 mg/dL (<5.55 mmol/L)] and other cardiovascular disease (CVD) risk factors in individuals aged 10 to <40 years in the T1D Exchange clinic registry. In 7223 participants, statin use was 2% in 10 to <18 year olds, 4% in 18 to <25 year olds, and 21% in 25 to <40 year olds. Individuals not on statin therapy with LDL-C above target were more likely to have ≥1 additional CVD risk factor(s) than those with LDL-C in the target range for all age groups (all P < 0.01). While most individuals not on statin therapy had LDL-C in the target range, those who did not were more likely to have ≥1 additional CVD risk factor(s), and therefore longitudinal study of lipid levels and statin use is needed to see if treatment of dyslipidaemia to target LDL-C levels may lower the risk of future CVD in individuals aged 10 to <40 years with type 1 diabetes.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  dyslipidaemia; type 1 diabetes

Mesh:

Substances:

Year:  2018        PMID: 30039636      PMCID: PMC7059116          DOI: 10.1111/dom.13475

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  5 in total

1.  Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report.

Authors: 
Journal:  Pediatrics       Date:  2011-11-14       Impact factor: 7.124

Review 2.  Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association.

Authors:  Sarah D de Ferranti; Ian H de Boer; Vivian Fonseca; Caroline S Fox; Sherita Hill Golden; Carl J Lavie; Sheela N Magge; Nikolaus Marx; Darren K McGuire; Trevor J Orchard; Bernard Zinman; Robert H Eckel
Journal:  Circulation       Date:  2014-08-11       Impact factor: 29.690

Review 3.  9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2018.

Authors: 
Journal:  Diabetes Care       Date:  2018-01       Impact factor: 19.112

Review 4.  12. Children and Adolescents: Standards of Medical Care in Diabetes-2018.

Authors: 
Journal:  Diabetes Care       Date:  2018-01       Impact factor: 19.112

5.  The T1D Exchange clinic registry.

Authors:  Roy W Beck; William V Tamborlane; Richard M Bergenstal; Kellee M Miller; Stephanie N DuBose; Callyn A Hall
Journal:  J Clin Endocrinol Metab       Date:  2012-09-20       Impact factor: 5.958

  5 in total
  1 in total

Review 1.  Preventing Cardiovascular Complications in Type 1 Diabetes: The Need for a Lifetime Approach.

Authors:  Scott T Chiesa; M Loredana Marcovecchio
Journal:  Front Pediatr       Date:  2021-06-09       Impact factor: 3.418

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.